Skip to main content
. 2011 Mar 7;17(9):1174–1179. doi: 10.3748/wjg.v17.i9.1174

Figure 4.

Figure 4

Cumulative incidence of maintaining non-recurrent status in patients with anorectal stricture. The cumulative incidence of fistula recurrence was 53.9%/5 years with infliximab (IFX) (n = 19) and 55.0%/5 years and 62.5%/10 years without IFX (n = 21), respectively.